The aetiology of sarcoidosis is uncertain; current thinking implicates exposure of genetically susceptible hosts to environmental factors. The nuclear factor kappa B (NF-kB) family of transcription factors are critical regulators of immediate transcriptional responses in inflammatory situations and immune responses. Inhibitor kappa B-alpha (IkB-a) inhibits NF-kB and plays a major role in controlling its activity. We investigated IkB-a promoter polymorphisms using sequence-specific primer-polymerase chain reaction, at positions À881 (A/G), À826 (C/T), and À297 (C/T) in Caucasian sarcoidosis patients (UK and Dutch [NL]), each with their own controls. Disease severity at presentation was assigned using chest radiography and pulmonary function indices. In the combined populations, the À297T allele carriage was more prevalent in patients than in controls (P ¼ 0.008). Three common haplotypes were found, of which haplotype 2 (GTT) was significantly associated with sarcoidosis in comparison with control subjects (P ¼ 0.01). Subgroup analysis revealed that the À826T allelic carriage was most prevalent in stage II disease, and more prevalent in stage III than in stage IV (P ¼ 0.01). The À826T allelic carriage did not show any association with lung function. These results indicate that the NF-kB activation pathway might be associated with the inflammation of sarcoidosis.
Introduction
Sarcoidosis is a multisystem granulomatous disease of unknown aetiology. Current pathogenetic thinking is that it results from exposure of genetically susceptible hosts to particular environmental factors. [1] [2] [3] Numerous environmental factors, including transmissible agents, infectious organisms, and noninfectious environmental agents, are seen as potential etiological agents. [4] [5] [6] [7] Chronic inflammation resulting in granuloma formation is the cardinal histological feature. 3 The lung is commonly affected, with lymphocyte accumulation, principally of the CD4+ phenotype, and inflammatory cytokines release. 8, 9 Bronchoalveolar lavage (BAL) studies have disclosed prominent activation of alveolar macrophages and T cells, with a predominant Th1 cytokine profile. 10, 11 The inflammatory response is characterized by increased production of proinflammatory cytokines, including interleukin (IL)-2, interferon (IFN-g), tumour necrosis factor (TNF)-a, interleukin IL1b, interleukin (IL)-6, and chemokines that amplify the inflammatory process and recruit monocytes from the periphery. [12] [13] [14] [15] [16] [17] Cytokine gene expression is regulated via several mechanisms. The nuclear factor kappa B (NF-kB) transcription factor family is a critical regulator of immunologically mediated immediate transcriptional responses. 18 In resting cells, NF-kB is present in an inactive cytoplasmic form bound to an inhibitor protein termed inhibitor kB (IkB), which masks the nuclear localization sequence of NF-kB, thereby retaining it in the cytoplasm and preventing DNA binding. Upon phosphorylation, IkB degrades, allowing nuclear localization of NF-kB and initiation of transcription. 18 Several IkB proteins are involved in the control of NF-kB activity. IkB-alpha (IkB-a) is an absolute requirement for normal termination of the NF-kB response. 19 IkB-a knockout mice die 7-10 days after birth with severe widespread dermatitis and increased levels of TNF-a mRNA in the skin.
Activation of the NF-kB signalling pathway has been linked to the pathogenesis of sarcoidosis. In a functional genomics study, peripheral blood NF-kB expression was higher in stages II and III than in stage 1 disease. 20 In a different study, NF-kB expression was twice as high in untreated and treated patients with sarcoidosis compared to the control subjects. 21 NF-kB activity and nuclear localization is evident in pulmonary CD4+ T lymphocytes from sarcoid patients but not in peripheral blood CD4+ T lymphocytes or normal control samples. 12 In sarcoidosis, NF-kB-dependent signalling is necessary for TNF-a and IL-6 production by alveolar macrophages and IFN-g production by alveolar T cells. 22 We hypothesized that allelic differences in the IkB-a gene promoter might modulate IkB-a expression influencing the intensity of inflammatory responses, which might in turn contribute to susceptibility to sarcoidosis or disease severity. Three single-nucleotide polymorphisms have been identified in the promoter region of IkB-a gene at positions À881, À826, and À297. 23 The aim of our study was to identify associations between IkB-a promoter polymorphisms and (1) disease susceptibility, (2) disease severity characteristics such as chest radiographic stages and pulmonary function tests at presentation.
Subjects and methods

UK patients and control subjects
In all, 115 unrelated UK Caucasian sarcoid patients were investigated. In all patients, the diagnosis of pulmonary sarcoidosis was established when clinical findings were supported by histological evidence of noncaseating epithelioid cell granulomas. Verbal and written patient consent was obtained from all the subjects, and ethical approval for the study was given by the Ethics Committee of the Royal Brompton Hospital, London. Our hospital is a tertiary referral centre taking patients mainly from the southeast of the UK. The chest radiographic stages at presentation are presented in Table 1 .
The UK control population comprised 99 UK Caucasian subjects, again mainly collected from the southeast of the UK. All had given their written consent.
Dutch patients and control subjects
A total of 90 unrelated Dutch Caucasian sarcoid patients were included in the study. The diagnosis of pulmonary sarcoidosis was established when clinical findings were supported by histological evidence except in 10 patients who presented with classic Lö fgren's syndrome (fever, erythema nodosum, arthralgia, and bilateral hilar lymphadenopathy). Verbal and written patient consent was obtained from all the subjects and authorization was given by the Ethics Committee of the Sint Antonius Hospital, Nieuwegein (Utrecht region). The chest radiographic stages at presentation are presented in Table 1 .
The Dutch control group comprised 102 Caucasian donors from the Blood Transfusion Service in Utrecht, which takes donors mainly from the Utrecht region. All donors were routinely checked for health before donation, and gave their written consent.
Patients and controls from these cohorts were subjects in previous studies. [24] [25] [26] Chest radiographic scoring and lung function tests were as previously described. [24] [25] [26] For a total of 115 UK and 90 Dutch patients, chest radiograph data at presentation were available in 105 UK patients and 89 NL patients. Both groups of patients had lung function tests at the referral centre. FVC, FEV, and lungdiffusing capacity for carbon monoxide (DL CO ) were used to assess the presence of lung function impairment at presentation of disease. Lung function data at presentation were available in 106 UK patients and 51 NL patients.
Sequence-specific primers (SSPs) and polymerase chain reaction (PCR) Three IkB-a promoter polymorphisms were investigated, NCBI reference number of these polymorphisms at positions À881, À826, and À297 are rs3138053, rs2233406, and rs2233409 respectively. Polymorphisms were tested using SSPs and PCR that utilizes SSPs with 3 0 -end mismatches and identifies the presence of allelic variants through PCR amplification. The primers were combined to link polymorphic sites within IkB-a promoter. Combinations of forward and reverse allelespecific primers were used to identify the cis/trans orientation of the alleles and thus the haplotypes in the IkB-a promoter gene. Eight reactions were prepared to examine all the possible haplotypes. For the identification of the polymorphism at position À881, the sequencespecific forward primers 5 0 -CTT TTT CTG CGG GAG CAC AG and 5 0 -CTT TTT CTG CGG GAG CAC AA were combined with the sequence-specific reverse primers for position À297 5 0 -CCT GTC CCT CTG CAA GTG AA and 5 0 -CTG TCC CTC TGC AAG TGA G at a final concentration of 15 ng/ml leading to an expected PCR product size of 616 bp. For the identification of the polymorphism at position À826, we used the sequencespecific forward primers 5 0 -TT ATG AAC ACA ATA GCT ACT CTG C and 5 0 -CTT ATG AAC ACA ATA GCT ACT CTG T and in haplotype combination with position À297 primers at a final concentration of 40 ng/ml, leading to an expected PCR product size of 565 bp. In all primer mixes we included the control primers 5 0 -ATG ATG TTG ACC TTT CCA GGG and 5 0 -GCA ACT GAT GAA AAG TTA CAG AA at a final concentration of 4.5 ng/ml. All PCR reactions were run under identical conditions as previously described. 27 
Data analysis
The genotype frequencies, phenotype frequencies, and the frequency of an allele in the chromosomal pool of each population (allele frequency) were determined by direct counting for both control and sarcoidosis groups. All genotype frequencies were tested for conformation to Hardy-Weinberg equilibrium. The carrier frequency of each haplotype was determined by direct counting. Statistical analysis was performed using w 2 contingency table analysis with the appropriate number of degrees of freedom. Analysis of pulmonary function data was performed using the Mann-Whitney U test. A P-value of o0.05 was considered significant.
Results
Distribution of IjB-a promoter polymorphisms in British and Dutch populations
The genotype and allelic carriage of the investigated IkB-a promoter polymorphisms in the British and Dutch sarcoidosis and control populations are presented in Table 2 . Genotype data from all populations conformed to Hardy-Weinberg equilibrium. The haplotype frequencies are shown in Table 3 ; three common haplotypes (45%) and four rare haplotypes were found.
Disease susceptibility British population results
In the British sarcoidosis population, the À297T allelic carriage was more prevalent in patients than in controls (w 2 ¼ 4.8 with 1 df, P ¼ 0.03) ( Table 3 ). In addition, we found a trend towards an increase in haplotype 2 in patients compared with control (w 2 ¼ 3.9 with 1 df, P ¼ 0.05).
Dutch population results
In the Dutch sarcoidosis population, À297T allelic carriage and haplotype 2 also show a trend to be higher in sarcoidosis patients (w 2 ¼ 2.2 with 1 df, P ¼ 0.1 and w 2 ¼ 2.2 with 1 df, P ¼ 0.1, respectively).
In the combined British and Dutch sarcoidosis populations, the À297T allelic carriage showed a strong association with disease (P ¼ 0.008) (Table 3) . Also, in the combined British and Dutch populations, the À881G allelic carriage and À826T allelic carriage were more prevalent in sarcoidosis than in controls (P ¼ 0.05, 0.04, respectively). In addition, haplotype 2 showed a higher prevalence in patients than in controls (P ¼ 0.01). No significant differences were found in the frequencies of other haplotypes.
Disease severity
We assessed relations between IkB-a promoter polymorphisms and disease severity (as judged by radiographic staging and pulmonary function tests indices).
Radiology. As shown in Figure 1 , in analysis of patients with parenchymal lung disease, the À826T allelic carriage across the stages of sarcoid from II to IV shows a significant difference between the groups. There was a progressive decline in the À826T allele carriage from II to IV (P ¼ 0.01, w 2 ¼ 8.4). The decline was similar for both populations, except for stage IV in the Dutch sarcoid population which has only one patient. No association was found in patients without parenchymal lung disease (stages 0 and I) and any of the investigated polymorphisms (data not shown).
Pulmonary function tests. The À826T allele did not show any association with lung function tests. As shown in Figure 2 , no association was found with DL CO . The other investigated IkB-a promoter polymorphisms, at nucleotide positions À881 and À297, revealed no differences with lung function tests (data not shown). IkB-a promoter polymorphisms in sarcoidosis A Abdallah et al
Discussion
In the present study, we have investigated associations between three potentially functional IkBa promoter polymorphisms, and the presence of radiological stages and severity of sarcoidosis in clinically well-defined subjects from the UK and the Netherlands. [24] [25] [26] The À297T allele was more prevalent in sarcoidosis patients than controls. By contrast, the À826T allele exhibited a descending order of frequency from stage II to stage IV disease. Analysis of IkB-a promoter haplotypes disclosed an association between haplotype 2 and the presence of sarcoidosis, but this haplotype was not distinguished by a greater functional impairment. Thus, this gene appears to be linked to the presence rather than the severity of sarcoidosis. As Rutherford RM and colleagues found that NF-kB expression is higher in stages II and III than in stage I disease, it would be of great interest to investigate the role of these polymorphisms in the function of the gene. 20 The prevalence of IkB-a promoter polymorphisms was first reported by Mozzato-Chamay et al 23 in an African population, in studies of inflammation and fibrosis trachoma and silicosis. We found the frequencies of these polymorphisms, including notably the À826T allele, to be substantially higher in our Caucasian control subjects than in African control subjects. 23 It is well known that the severity of sarcoidosis varies in different populations. For example, Afro-American individuals are more severely affected by sarcoidosis. 28, 29 Afro-Americans are more likely to be younger at diagnosis, have widespread extrathoracic disease, and require treatment with corticosteroids. 30 If the À826T allele is protective against fibrotic disease in sarcoidosis (stage IV), a lower prevalence of that allele in AfroAmericans might explain and contribute to a higher likelihood of end-stage fibrotic disease in this ethnic population.
Promoter polymorphisms of the IkB-a gene are of great immunogenetic interest, as there is strong evidence for an anti-inflammatory effect of IkBa/NF-kB-dependent mechanisms in the alveolar epithelial cells. [31] [32] [33] As these polymorphisms are associated with sarcoidosis, it may be argued that similarities could be drawn with other diseases involving inflammation and fibrosis.
The results as presented in this study have reinforced the need for a molecular scientific approach, including molecular genetics, to gain an understanding of disease cause and progression. The use of a more precise disease phenotype has stimulated scientists to rethink concepts of pathogenesis and re-explore the relative contributions of different genes and polymorphisms to this disease. Our group recently found an increased frequency of the uncommon TNF À857T allele in British and Dutch patients with sarcoidosis. 25 One of the most thoroughly investigated TNF promoter polymorphisms is the change from C to A at nucleotide position 863. 34 Udalova et al 34 demonstrated a clear effect of this nucleotide change on the relative binding affinity of different forms of the NFkB complex. It was shown that the p50-p50 homodimeric form of this complex, which acts as a transcriptional repressor, had a significantly decreased affinity to its DNA binding site for the À863A allele. As the p50-p50 homodimer acts as a transcriptional repressor on binding to its regulatory site in the promoter region of the TNF gene, decreased binding is thought to result in increased TNF-a production. 34 It is possible that the IkBa promoter polymorphisms might have similar effect on the affinity of this or other nuclear transcription regulatory factors, but presently there are no data available on this.
There are three known NF-kB-binding motifs in the promoter region of IkB-a gene; kB1, kB2, and kB3. The À297 polymorphism is located only 13 bp downstream of the kB2 motif and 72 bp upstream of the kB3 motif. As promoter polymorphisms, the potential functionality of these polymorphisms is high and they may affect the transcription activity of the gene. It is of great interest to investigate for any other nuclear transcription regulatory factor binding site in the IkB-a promoter and whether these polymorphisms affect the activity of this binding site.
The most frequently reported immunogenetic associations with sarcoidosis have been found with HLA Class II alleles on chromosome 6, but these associations have varied in reported studies of patients from different races and populations. 2 Previous linkage studies in familial sarcoidosis have confirmed the importance of these loci. 35 In addition, a recent genome-wide linkage study has pointed to the importance of the MHC for candidate genes in sarcoidosis, based on the observation that the greatest linkage score was found in this region. 2 However, the IkB-a gene is localized to chromosome 14, and one can therefore hypothesize that the contribution of the IkB-a gene to sarcoidosis phenotypes may be acting downstream of the primary causative gene.
In conclusion, this is the first study of multiple IkB-a promoter polymorphisms in sarcoidosis in two different IkB-a promoter polymorphisms in sarcoidosis A Abdallah et al populations. In combined British and Dutch patients, we demonstrated a significant association of IkB-a promoter polymorphisms with the development of sarcoidosis and lung disease type. The results on the IkB-a promoter polymorphism may indicate a novel susceptibility marker for parenchymal sarcoidosis. This polymorphism might modulate transcription of the gene, but further studies on its functionality and association with NF-kBmediated inflammatory responses are necessary, as well as correlation of these polymorphisms with mRNA and protein expression of the IkB-a gene. Future studies of the clinical relevance and possible therapeutic consequences of this observation are required.
